MOZ regulates B-cell progenitors and, consequently, Moz haploinsufficiency dramatically retards MYC-induced lymphoma

Bilal N Sheikh1, Stanley C W Lee1, Farrah El-Saafin1

  • 1The Walter and Eliza Hall Institute of Medical Research, Melbourne, Victoria, Australia; and Department of Medical Biology, and.

Blood
|January 22, 2015
PubMed

Insights

Wild-type MOZ protein is crucial for B-cell progenitor proliferation and hematopoietic malignancy. Inhibiting MOZ may reduce the proliferative capacity of MEIS1 and HOX-driven lymphoma and leukemia cells.

Area of Science:

  • Hematology
  • Molecular Biology
  • Oncology

Background:

  • The histone acetyltransferase MOZ (MYST3, KAT6A) is implicated in aggressive acute myeloid leukemia due to chromosomal translocations.
  • Wild-type MOZ's role in normal B-cell development and its potential contribution to hematopoietic malignancies remain under investigation.

Purpose of the Study:

  • To investigate the function of wild-type MOZ in regulating B-cell progenitor proliferation.
  • To determine MOZ's role in hematopoietic malignancy, specifically in the context of B-cell lymphoma.

Main Methods:

  • Utilized the Eμ-Myc mouse model of aggressive pre-B/B-cell lymphoma.
  • Assessed the impact of Moz haploinsufficiency on mouse survival and B-cell progenitor proliferation.
  • Analyzed gene expression overlap between MOZ, MLL1, and menin, focusing on Meis1 regulation.

Main Results:

  • Loss of one Moz allele significantly increased median survival in the Eμ-Myc lymphoma model (3.9-fold).
  • MOZ is essential for maintaining B-cell progenitor proliferative capacity, even with c-MYC overexpression.
  • B-cell progenitor numbers were reduced in Moz haploinsufficient animals.
  • MOZ directly maintains the expression of genes vital for normal B-cell development, including Meis1.
  • MOZ was found to localize to the Meis1 locus and maintain its expression in pre-B cells.

Conclusions:

  • Wild-type MOZ plays a critical role in maintaining B-cell progenitor proliferation and is involved in hematopoietic malignancy.
  • MOZ's regulation of Meis1 expression is a key mechanism underlying its function in B-cell development and potentially in leukemogenesis.
  • Partial inhibition of MOZ could be a therapeutic strategy against MEIS1 and HOX-driven lymphoma and leukemia.

Related Concept Videos

Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.5K
Induced Pluripotent Stem Cells01:06

Induced Pluripotent Stem Cells

Stem cells are undifferentiated cells that divide and produce different cell types. Ordinarily, cells that have differentiated into a specific cell type are terminally differentiated; however, scientists have found a way to reprogram these mature cells so that they dedifferentiate and return to an unspecialized, proliferative state. These cells are pluripotent like embryonic stem cells—able to produce all cell types—and are called induced pluripotent stem cells (iPSCs).
Somatic...
6.4K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
5.1K
Regulation of Hematopoietic Stem Cells01:01

Regulation of Hematopoietic Stem Cells

All blood and immune cells are produced from the multipotent hematopoietic stem cells (HSCs) by the process of hematopoiesis. However, they all have a limited life span. In addition, many are depleted in immune surveillance or combatting an injury or infection. This makes blood one of the most regenerative tissues. Hematopoiesis helps replenish these blood and immune cells, restoring the body's normal functioning. However, overproduction of blood and immune cells can make them cancerous or...
4.5K
Mismatch Repair01:20

Mismatch Repair

Organisms are capable of detecting and fixing nucleotide mismatches that occur during DNA replication. This sophisticated process requires identifying the new strand and replacing the erroneous bases with correct nucleotides. Mismatch repair is coordinated by many proteins in both prokaryotes and eukaryotes.
The Mutator Protein Family Plays a Key Role in DNA Mismatch Repair
The human genome has more than 3 billion base pairs of DNA per cell. Prior to cell division, that vast amount of genetic...
7.2K
Mouse Models of Cancer Study02:43

Mouse Models of Cancer Study

Mice have long served as models for studying human biology and pathology because of their phylogenetic and physiological similarity with humans. They are also easy to maintain and breed in the laboratory, and hence, many inbred strains are now available for research. Studies on mice have contributed immeasurably to our understanding of cancer biology.
The development of transgenic, knockout, and knock-in mice has led to an exponential increase in their use as model organisms in research,...
6.8K